Document Generated: 2024-03-21

Changes to legislation: There are currently no known outstanding effects for the Commission Delegated Regulation (EU) 2020/692, ANNEX IV. (See end of Document for details)

ANNEX IV

PART A

1. Minimum periods of disease freedom of the third country or territory of origin or zone thereof, as provided for in Article 22(1) for **ungulates other than equine animals**:

	1. Bovine animals	2. Ovine animals	3. Caprine animals	4. Porcine animals	5. Camelid animals	6. Cervid animals	7. Ungulates other than those referred to in columns 1, 2, 3, 4, 5, 6 ^a
Foot and mouth disease	24 months ^b	24 months ^b	24 months ^b	24 months ^b	24 months ^b	24 months ^b	24 months ^b
Infection with rinderpest virus	12 months	12 months	12 months	12 months	12 months	12 months	12 months
Infection with Rift Valley fever virus	12 months	12 months	12 months	NA	12 months	12 months	12 months
Infection with Mycoplasm mycoides subsp. mycoides SC (Contagious bovine pleuropneu	ıs	NA	NA	NA	NA	NA	12 months
Infection with peste des petits ruminants virus	NA	12 months	12 months	NA	12 months	12 months	NA

a only applicable for listed species in accordance with the Annex to Commission Implementing Regulation (EU) 2018/1882

NA = not applicable

b or specific conditions are provided by the competent authority of the third country or territory in accordance with Part B as provided for in Article 22(3)

Document Generated: 2024-03-21

Changes to legislation: There are currently no known outstanding effects for the Commission Delegated Regulation (EU) 2020/692, ANNEX IV. (See end of Document for details)

Sheep pox and goat pox	NA	12 months	12 months	NA	NA	NA	NA
Contagious caprine pleuropneu		12 months	12 months	NA	NA	NA	12 months
African swine fever	NA	NA	NA	12 months	NA	NA	NA
Classical swine fever	NA	NA	NA	12 months ^b	NA	NA	12 months
Infection with lumpy skin disease virus	12 months	NA	NA	NA	NA	NA	NA

a only applicable for listed species in accordance with the Annex to Commission Implementing Regulation (EU) 2018/1882

NA = not applicable

2. Minimum periods of disease freedom of the third country or territory of origin or zone thereof in accordance with Article 22(2)(a) for **equine animals**:

African horse sickness	24 months

3. Minimum periods during which disease has not been reported in the third country or territory of origin or zone thereof in accordance with Article 22(2)(b) for **equine** animals:

Venezuelan equine encephalomyelitis	24 months
Infection with <i>Burkholderia mallei</i> (Glanders)	36 months ^a
Dourine	24 months ^a
Surra (Trypanosoma evansi)	24 months ^a

a or specific conditions are provided by the competent authority of the third country or territory in accordance with Part B as provided for in Article 22(3)

PART B

Specific conditions to be provided by the competent authority of the third country or territory where the third country or territory or zone thereof has been free from certain diseases for less than the period set out in the table in Part A of this Annex as referred to in Article 22(3):

b or specific conditions are provided by the competent authority of the third country or territory in accordance with Part B as provided for in Article 22(3)

Document Generated: 2024-03-21

Changes to legislation: There are currently no known outstanding effects for the Commission
Delegated Regulation (EU) 2020/692, ANNEX IV. (See end of Document for details)

Foot and mouth disease	Supplementary information to determine the date from which the third country or territory or zone thereof is considered to be free from foot and mouth disease.			
Classical swine fever	(a) (b)	supplementary information to determine the date from which the third country or territory or zone thereof is considered to be free from classical swine fever; the animals intended for entry into the Union have reacted negatively to a test for the detection of classical swine fever, carried out within a period of 30 days prior to the date of dispatch to the Union.		
Infection with Burkholderia mallei (Glanders)	(a) (b)	the disease not reported in the establishment of origin during a period of at least 6 months prior to the date of dispatch to the Union; the Commission has recognised the surveillance programme carried out in breeding equine animals in the establishment of origin to demonstrate absence of infection during that period of 6 months.		
Dourine	(a) (b)	the disease not reported in the establishment of origin for a period at least 6 months prior to the date of dispatch to the Union; the Commission has recognised the surveillance programme carried out to demonstrate the absence of infection in the establishment of origin during that period of 6 months.		
Surra (Trypanosoma evansi)	(a) (b)	the disease has not been reported in the establishment of origin for a period of at least the 6 months prior to the date of dispatch to the Union; the Commission has recognised the surveillance programme carried out to demonstrate the absence of infection in the establishment of origin during that period of 6 months.		

Document Generated: 2024-03-21

Changes to legislation: There are currently no known outstanding effects for the Commission Delegated Regulation (EU) 2020/692, ANNEX IV. (See end of Document for details)

PART C

1. Requirements as regards the absence of vaccination for the third country or territory of origin or zone thereof and for the **ungulates other than equine animals** as referred to in Article 22(4)(a):

	1. Bovine animals	2. Ovine animals	3. Caprine animals	4. Porcine animals	5. Camelid animals	6. Cervid animals	7. Ungulates others than those referred to in columns 1, 2, 3, 4, 5, 6 ^a
Foot and mouth disease	NV/NVA	NV/NVA	NV/NVA	NV/NVA	NV/NVA	NV/NVA	NV/NVA
Infection with rinderpest virus	NV/NVA	NV/NVA	NV/NVA	NV/NVA	NV/NVA	NV/NVA	NV/NVA
Rift Valley fever virus	NV/NVA	NV/NVA	NV/NVA	NA	NV/NVA	NV/NVA	NV/NVA
Infection with Mycoplasm mycoides subsp. mycoides SC (Contagiou bovine pleuropneu	as	NA	NA	NA	NA	NA	NV/NVA
Infection with peste des petits ruminants virus	NA	NV/NVA	NV/NVA	NA	NV/NVA	NV/NVA	NA

a only applicable for listed species in accordance with the Annex to Commission Implementing Regulation (EU) 2018/1882

NV = for a period of at least 12 months prior to the date of dispatch to the Union, no vaccination has been carried out in the third country, territory or zone and no vaccinated animals entered into the third country territory or zone

NVA = the animals intended for the entry into the Union have not been vaccinated

NA = not applicable

ANNEX IV PART C

Document Generated: 2024-03-21

Changes to legislation: There are currently no known outstanding effects for the Commission Delegated Regulation (EU) 2020/692, ANNEX IV. (See end of Document for details)

Sheep pox and goat pox	NA	NV/NVA	NV/NVA	NA	NA	NA	NA
Contagious caprine pleuropneu		NV/NVA	NV/NVA	NA	NA	NA	NV/NVA
Classical swine fever	NA	NA	NA	NV/NVA	NA	NA	NA
Infection with lumpy skin disease virus	NVA	NA	NA	NA	NA	NA	NA

a only applicable for listed species in accordance with the Annex to Commission Implementing Regulation (EU) 2018/1882

NV = for a period of at least 12 months prior to the date of dispatch to the Union, no vaccination has been carried out in the third country, territory or zone and no vaccinated animals entered into the third country territory or zone

NVA = the animals intended for the entry into the Union have not been vaccinated

NA = not applicable

2. Requirements as regards the absence of vaccination for the third country or territory of origin or zone thereof and for the **equine animals** as referred to in Article 22(4)(b):

African horse sickness	_	No systematic vaccination has been carried out in in the third country or territory of origin or zone thereof during a period of at least 12 months prior to the date of dispatch to the Union and the equine animals have not been vaccinated at least in the last 40 days prior to dispatch to the Union
Venezuelan equine encephalomyelitis	_	The equine animals have not been vaccinated at least in the last 60 days prior to dispatch to the Union

Changes to legislation:

There are currently no known outstanding effects for the Commission Delegated Regulation (EU) 2020/692, ANNEX IV.